Sven Borchmann

Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer

Lydia Meder, Philipp Schuldt, Martin Thelen et al. · Cancer Research · 2018 · 172 citations · Full text

Medicine, Immunology, Oncology +17

Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials

Stephanie Sasse, Paul J. Bröckelmann, Helen Goergen et al. · Journal of Clinical Oncology · 2017 · 142 citations

Medicine, Hematology, Oncology +12

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Boris Böll, Helen Goergen, Karolin Behringer et al. · Blood · 2016 · 115 citations · Full text

Medicine, Geriatric Medicine, Oncology +13

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

Peter Borchmann, Justin Ferdinandus, Gundolf Schneider et al. · The Lancet · 2024 · 114 citations · Full text

Medicine, Oncology, Pharmacology +15

MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

Johannes Brägelmann, Carina Lorenz, Sven Borchmann et al. · Nature Communications · 2021 · 76 citations · Full text

Medicine, Cancer Biology, Oncology +17